Diagnosis and management of dementia with Lewy bodies

Ian G. McKeith, Bradley F. Boeve, Dennis W. DIckson, Glenda Halliday, John Paul Taylor, Daniel Weintraub, Dag Aarsland, James Galvin, Johannes Attems, Clive G. Ballard, Ashley Bayston, Thomas G. Beach, Frédéric Blanc, Nicolaas Bohnen, Laura Bonanni, Jose Bras, Patrik Brundin, David Burn, Alice Chen-Plotkin, John E. Duda & 43 others Omar Ali El-Agnaf, Howard Feldman, Tanis J. Ferman, Dominic Ffytche, Hiroshige Fujishiro, Douglas Galasko, Jennifer G. Goldman, Stephen N. Gomperts, Neill R. Graff-Radford, Lawrence S. Honig, Alex Iranzo, Kejal Kantarci, Daniel Kaufer, Walter Kukull, Virginia M.Y. Lee, James B. Leverenz, Simon Lewis, Carol Lippa, Angela Lunde, Mario Masellis, Eliezer Masliah, Pamela McLean, Brit Mollenhauer, Thomas J. Montine, Emilio Moreno, Etsuro Mori, Melissa Murray, John T. O'Brien, Sotoshi Orimo, Ronald B. Postuma, Shankar Ramaswamy, Owen A. Ross, David P. Salmon, Andrew Singleton, Angela Taylor, Alan Thomas, Pietro Tiraboschi, Jon B. Toledo, John Q. Trojanowski, Debby Tsuang, Zuzana Walker, Masahito Yamada, Kenji Kosaka

Research output: Contribution to journalReview article

433 Citations (Scopus)

Abstract

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123 iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

Original languageEnglish
Pages (from-to)88-100
Number of pages13
JournalNeurology
Volume89
Issue number1
DOIs
Publication statusPublished - 4 Jul 2017

Fingerprint

Lewy Body Disease
REM Sleep Behavior Disorder
Lewy Bodies
Myocardial Perfusion Imaging
Neurobiology
Expert Testimony
Substantia Nigra
Neuroimaging
Iodine
Caregivers
Consensus
Alzheimer Disease
Randomized Controlled Trials
Biomarkers
Clinical Trials
Pathology
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

McKeith, I. G., Boeve, B. F., DIckson, D. W., Halliday, G., Taylor, J. P., Weintraub, D., ... Kosaka, K. (2017). Diagnosis and management of dementia with Lewy bodies. Neurology, 89(1), 88-100. https://doi.org/10.1212/WNL.0000000000004058

Diagnosis and management of dementia with Lewy bodies. / McKeith, Ian G.; Boeve, Bradley F.; DIckson, Dennis W.; Halliday, Glenda; Taylor, John Paul; Weintraub, Daniel; Aarsland, Dag; Galvin, James; Attems, Johannes; Ballard, Clive G.; Bayston, Ashley; Beach, Thomas G.; Blanc, Frédéric; Bohnen, Nicolaas; Bonanni, Laura; Bras, Jose; Brundin, Patrik; Burn, David; Chen-Plotkin, Alice; Duda, John E.; Ali El-Agnaf, Omar; Feldman, Howard; Ferman, Tanis J.; Ffytche, Dominic; Fujishiro, Hiroshige; Galasko, Douglas; Goldman, Jennifer G.; Gomperts, Stephen N.; Graff-Radford, Neill R.; Honig, Lawrence S.; Iranzo, Alex; Kantarci, Kejal; Kaufer, Daniel; Kukull, Walter; Lee, Virginia M.Y.; Leverenz, James B.; Lewis, Simon; Lippa, Carol; Lunde, Angela; Masellis, Mario; Masliah, Eliezer; McLean, Pamela; Mollenhauer, Brit; Montine, Thomas J.; Moreno, Emilio; Mori, Etsuro; Murray, Melissa; O'Brien, John T.; Orimo, Sotoshi; Postuma, Ronald B.; Ramaswamy, Shankar; Ross, Owen A.; Salmon, David P.; Singleton, Andrew; Taylor, Angela; Thomas, Alan; Tiraboschi, Pietro; Toledo, Jon B.; Trojanowski, John Q.; Tsuang, Debby; Walker, Zuzana; Yamada, Masahito; Kosaka, Kenji.

In: Neurology, Vol. 89, No. 1, 04.07.2017, p. 88-100.

Research output: Contribution to journalReview article

McKeith, IG, Boeve, BF, DIckson, DW, Halliday, G, Taylor, JP, Weintraub, D, Aarsland, D, Galvin, J, Attems, J, Ballard, CG, Bayston, A, Beach, TG, Blanc, F, Bohnen, N, Bonanni, L, Bras, J, Brundin, P, Burn, D, Chen-Plotkin, A, Duda, JE, Ali El-Agnaf, O, Feldman, H, Ferman, TJ, Ffytche, D, Fujishiro, H, Galasko, D, Goldman, JG, Gomperts, SN, Graff-Radford, NR, Honig, LS, Iranzo, A, Kantarci, K, Kaufer, D, Kukull, W, Lee, VMY, Leverenz, JB, Lewis, S, Lippa, C, Lunde, A, Masellis, M, Masliah, E, McLean, P, Mollenhauer, B, Montine, TJ, Moreno, E, Mori, E, Murray, M, O'Brien, JT, Orimo, S, Postuma, RB, Ramaswamy, S, Ross, OA, Salmon, DP, Singleton, A, Taylor, A, Thomas, A, Tiraboschi, P, Toledo, JB, Trojanowski, JQ, Tsuang, D, Walker, Z, Yamada, M & Kosaka, K 2017, 'Diagnosis and management of dementia with Lewy bodies', Neurology, vol. 89, no. 1, pp. 88-100. https://doi.org/10.1212/WNL.0000000000004058
McKeith IG, Boeve BF, DIckson DW, Halliday G, Taylor JP, Weintraub D et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017 Jul 4;89(1):88-100. https://doi.org/10.1212/WNL.0000000000004058
McKeith, Ian G. ; Boeve, Bradley F. ; DIckson, Dennis W. ; Halliday, Glenda ; Taylor, John Paul ; Weintraub, Daniel ; Aarsland, Dag ; Galvin, James ; Attems, Johannes ; Ballard, Clive G. ; Bayston, Ashley ; Beach, Thomas G. ; Blanc, Frédéric ; Bohnen, Nicolaas ; Bonanni, Laura ; Bras, Jose ; Brundin, Patrik ; Burn, David ; Chen-Plotkin, Alice ; Duda, John E. ; Ali El-Agnaf, Omar ; Feldman, Howard ; Ferman, Tanis J. ; Ffytche, Dominic ; Fujishiro, Hiroshige ; Galasko, Douglas ; Goldman, Jennifer G. ; Gomperts, Stephen N. ; Graff-Radford, Neill R. ; Honig, Lawrence S. ; Iranzo, Alex ; Kantarci, Kejal ; Kaufer, Daniel ; Kukull, Walter ; Lee, Virginia M.Y. ; Leverenz, James B. ; Lewis, Simon ; Lippa, Carol ; Lunde, Angela ; Masellis, Mario ; Masliah, Eliezer ; McLean, Pamela ; Mollenhauer, Brit ; Montine, Thomas J. ; Moreno, Emilio ; Mori, Etsuro ; Murray, Melissa ; O'Brien, John T. ; Orimo, Sotoshi ; Postuma, Ronald B. ; Ramaswamy, Shankar ; Ross, Owen A. ; Salmon, David P. ; Singleton, Andrew ; Taylor, Angela ; Thomas, Alan ; Tiraboschi, Pietro ; Toledo, Jon B. ; Trojanowski, John Q. ; Tsuang, Debby ; Walker, Zuzana ; Yamada, Masahito ; Kosaka, Kenji. / Diagnosis and management of dementia with Lewy bodies. In: Neurology. 2017 ; Vol. 89, No. 1. pp. 88-100.
@article{4c06bc5e35e848bb818a422f1b533fe0,
title = "Diagnosis and management of dementia with Lewy bodies",
abstract = "The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123 iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.",
author = "McKeith, {Ian G.} and Boeve, {Bradley F.} and DIckson, {Dennis W.} and Glenda Halliday and Taylor, {John Paul} and Daniel Weintraub and Dag Aarsland and James Galvin and Johannes Attems and Ballard, {Clive G.} and Ashley Bayston and Beach, {Thomas G.} and Fr{\'e}d{\'e}ric Blanc and Nicolaas Bohnen and Laura Bonanni and Jose Bras and Patrik Brundin and David Burn and Alice Chen-Plotkin and Duda, {John E.} and {Ali El-Agnaf}, Omar and Howard Feldman and Ferman, {Tanis J.} and Dominic Ffytche and Hiroshige Fujishiro and Douglas Galasko and Goldman, {Jennifer G.} and Gomperts, {Stephen N.} and Graff-Radford, {Neill R.} and Honig, {Lawrence S.} and Alex Iranzo and Kejal Kantarci and Daniel Kaufer and Walter Kukull and Lee, {Virginia M.Y.} and Leverenz, {James B.} and Simon Lewis and Carol Lippa and Angela Lunde and Mario Masellis and Eliezer Masliah and Pamela McLean and Brit Mollenhauer and Montine, {Thomas J.} and Emilio Moreno and Etsuro Mori and Melissa Murray and O'Brien, {John T.} and Sotoshi Orimo and Postuma, {Ronald B.} and Shankar Ramaswamy and Ross, {Owen A.} and Salmon, {David P.} and Andrew Singleton and Angela Taylor and Alan Thomas and Pietro Tiraboschi and Toledo, {Jon B.} and Trojanowski, {John Q.} and Debby Tsuang and Zuzana Walker and Masahito Yamada and Kenji Kosaka",
year = "2017",
month = "7",
day = "4",
doi = "10.1212/WNL.0000000000004058",
language = "English",
volume = "89",
pages = "88--100",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of dementia with Lewy bodies

AU - McKeith, Ian G.

AU - Boeve, Bradley F.

AU - DIckson, Dennis W.

AU - Halliday, Glenda

AU - Taylor, John Paul

AU - Weintraub, Daniel

AU - Aarsland, Dag

AU - Galvin, James

AU - Attems, Johannes

AU - Ballard, Clive G.

AU - Bayston, Ashley

AU - Beach, Thomas G.

AU - Blanc, Frédéric

AU - Bohnen, Nicolaas

AU - Bonanni, Laura

AU - Bras, Jose

AU - Brundin, Patrik

AU - Burn, David

AU - Chen-Plotkin, Alice

AU - Duda, John E.

AU - Ali El-Agnaf, Omar

AU - Feldman, Howard

AU - Ferman, Tanis J.

AU - Ffytche, Dominic

AU - Fujishiro, Hiroshige

AU - Galasko, Douglas

AU - Goldman, Jennifer G.

AU - Gomperts, Stephen N.

AU - Graff-Radford, Neill R.

AU - Honig, Lawrence S.

AU - Iranzo, Alex

AU - Kantarci, Kejal

AU - Kaufer, Daniel

AU - Kukull, Walter

AU - Lee, Virginia M.Y.

AU - Leverenz, James B.

AU - Lewis, Simon

AU - Lippa, Carol

AU - Lunde, Angela

AU - Masellis, Mario

AU - Masliah, Eliezer

AU - McLean, Pamela

AU - Mollenhauer, Brit

AU - Montine, Thomas J.

AU - Moreno, Emilio

AU - Mori, Etsuro

AU - Murray, Melissa

AU - O'Brien, John T.

AU - Orimo, Sotoshi

AU - Postuma, Ronald B.

AU - Ramaswamy, Shankar

AU - Ross, Owen A.

AU - Salmon, David P.

AU - Singleton, Andrew

AU - Taylor, Angela

AU - Thomas, Alan

AU - Tiraboschi, Pietro

AU - Toledo, Jon B.

AU - Trojanowski, John Q.

AU - Tsuang, Debby

AU - Walker, Zuzana

AU - Yamada, Masahito

AU - Kosaka, Kenji

PY - 2017/7/4

Y1 - 2017/7/4

N2 - The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123 iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

AB - The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123 iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

UR - http://www.scopus.com/inward/record.url?scp=85021876617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021876617&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004058

DO - 10.1212/WNL.0000000000004058

M3 - Review article

VL - 89

SP - 88

EP - 100

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -